The importance of obtaining complete biomarker test results prior to initiating first-line therapy in mNSCLC

About 1 in 2 patients with mNSCLC have biomarkers with approved, emerging, or evolving therapeutics.4,5

RET fusions are 1 of 9 driver alterations with FDA-approved therapies4,5*

*Current as of March 2023.
Emerging Therapeutics=currently being studied in clinical trials; Evolving Therapeutics=either proof-of-concept studies or in a very early clinical stage.
ALK=anaplastic lymphoma kinase; BRAF=B-Raf proto-oncogene; EGFR=endothelial growth factor receptor; ERBB2=erb-b2 receptor tyrosine kinase 2; HER2=human epidermal growth factor receptor 2; KRAS=Kirsten rat sarcoma; MET=MET proto-oncogene; mNSCLC=metastatic non–small cell lung cancer; NTRK=neurotrophic tyrosine receptor kinase; RET+=rearranged during transfection positive; ROS1=ROS proto-oncogene 1.

Contact a Representative
Contact a representative

Contact your local representative for more information about RET in mNSCLC.